Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2005 3
2006 5
2007 4
2008 2
2009 3
2010 3
2011 2
2012 4
2013 2
2014 4
2015 5
2016 6
2017 5
2018 6
2019 4
2020 4
2021 11
2022 3
2023 10
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
Ascierto PA, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro MT, Lebbè C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Gonzales Cao M, Minisini AM, De Placido S, Sanmamed MF, Mallardo D, Curvietto M, Melero I, Palmieri G, Grimaldi AM, Giannarelli D, Dummer R, Chiarion Sileni V. Ascierto PA, et al. Among authors: richtig e. J Clin Oncol. 2023 Jan 10;41(2):212-221. doi: 10.1200/JCO.21.02961. Epub 2022 Sep 1. J Clin Oncol. 2023. PMID: 36049147 Clinical Trial.
ASCO Congress 2018: melanoma treatment.
Richtig E. Richtig E. Memo. 2018;11(4):261-265. doi: 10.1007/s12254-018-0455-4. Epub 2018 Nov 20. Memo. 2018. PMID: 30595751 Free PMC article. Review.
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
Dummer R, Corrie P, Gutzmer R, Meniawy TM, Del Vecchio M, Lebbé C, Guida M, Dutriaux C, Dreno B, Meyer N, Ferrucci PF, Dalle S, Khattak MA, Grob JJ, Briscoe K, Larkin J, Mansard S, Lesimple T, Guidoboni M, Sabatini S, Richtig E, Herbst R, Lobo M, Askelson M, Ascierto PA, Maio M. Dummer R, et al. Among authors: richtig e. J Clin Oncol. 2023 Aug 10;41(23):3917-3929. doi: 10.1200/JCO.22.02199. Epub 2023 Jun 12. J Clin Oncol. 2023. PMID: 37307514 Clinical Trial.
Interferon for melanoma.
Richtig E, Langmann G. Richtig E, et al. Ophthalmology. 2010 Sep;117(9):1861. doi: 10.1016/j.ophtha.2010.03.074. Ophthalmology. 2010. PMID: 20816255 No abstract available.
New ways to strengthen old risk factors.
Richtig G, Richtig E. Richtig G, et al. Among authors: richtig e. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):13-14. doi: 10.1111/jdv.19585. J Eur Acad Dermatol Venereol. 2024. PMID: 38126689 No abstract available.
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.
Barth DA, Moik F, Steinlechner S, Posch F, Mayer MC, Sandner AM, Berton F, Schlintl V, Koch L, John N, Wurm R, Pichler M, Bauernhofer T, Reimann P, Wohlkönig C, Richtig E, Winder T, Preusser M, Jost PJ, Ay C, Gerger A, Terbuch A, Riedl JM. Barth DA, et al. Among authors: richtig e. J Immunother Cancer. 2023 Dec 14;11(12):e007765. doi: 10.1136/jitc-2023-007765. J Immunother Cancer. 2023. PMID: 38097343 Free PMC article.
87 results